STEMI

基本解释

Method: 70 ACS(STEMI, NSTEMI, UAP) patients and 20 SAPpatients were selected.
方法：選擇ACS患者70例，其中ST段擡高的急性心肌梗死(STEMI)患者32例，非ST段擡高的急性心肌梗死(NSTEMI)患者及不穩定型心絞痛(UAP)患者分別爲18、20例。
Tirofiban can improve the situation of myocardial reperfusion after PCI in patients with STEMI.
鹽酸替羅非班能明顯改善STEMI患者急診PCI後心肌組織的再灌注水平。
Conclusion:Tirofiban can improve the situation of myocardial reperfusion after PCI in patients with STEMI.
結論:鹽酸替羅非班能明顯改善STEMI患者急診PCI後心肌組織的再灌注水平。
Out of 373 patients with STEMI referred for primary PCI, 89 patients were presented with MACE during the period of follow-up( average incidence: 23. 9% ).
373例STEMI患者隨訪期縂心血琯事件發生89例(平均發生率23.;9%25);
Conclusion: Evaluation of hs-C-reactive protein on admission in STEMI patients undergoing primary PCI allows reliable risk stratification of these patients.
結論：接受直接PCI的STEMI患者入院時檢測超敏C反應蛋白水平能夠爲區分高危患者提供証據。